We are live on ! Find out more
DALS

DA32 Life Science Tech Acquisition Corp. Class A Common Stock

Delisted

DALS was delisted on the 28th of July, 2023.

47 hedge funds and large institutions have $166M invested in DA32 Life Science Tech Acquisition Corp. Class A Common Stock in 2022 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 6

60% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 5

10% more capital invested

Capital invested by funds: $151M → $166M (+$14.7M)

9% more funds holding

Funds holding: 4347 (+4)

Holders
47
Holders Change
+4
Holders Change %
+9.3%
% of All Funds
0.76%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
10
Increased
8
Reduced
5
Closed
6
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
HCM
51
Highbridge Capital Management
New York
-$881K -90,891 Closed
SCM
52
Soleus Capital Management
Connecticut
-$487K -50,000 Closed
PHK
53
Point72 Hong Kong
Hong Kong
-$118K -12,155 Closed

DALS Hedge Fund Activity: Q4 2022 in Review

47 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in DA32 Life Science Tech Acquisition Corp. Class A Common Stock (DALS) for Q4 2022, worth a combined $166M — up 9.7% from $151M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new DALS positions and 6 closed out — a net gain of 4 holders — while 8 added to existing stakes and 5 trimmed.

The largest buyer was Cowen Investment Management, adding an estimated $6.89M. The largest seller was RP Investment Advisors, exiting entirely with an estimated $4.04M sold.

  • 47 institutional investors held DA32 Life Science Tech Acquisition Corp. Class A Common Stock (DALS) as of Q4 2022, up from 43 in Q3 2022.
  • Funds reported $166M of DA32 Life Science Tech Acquisition Corp. Class A Common Stock stock for Q4 2022, up 9.7% quarter-over-quarter.
  • 10 funds opened new DA32 Life Science Tech Acquisition Corp. Class A Common Stock positions in Q4 2022 and 6 closed out, a net change of +4 holders.
  • The largest DA32 Life Science Tech Acquisition Corp. Class A Common Stock buyer in Q4 2022 was Cowen Investment Management, an estimated $6.89M added.
  • The largest DA32 Life Science Tech Acquisition Corp. Class A Common Stock seller in Q4 2022 was RP Investment Advisors, an estimated $4.04M sold.

Based on aggregated 13F filings for Q4 2022.